YSP Southeast Asia Holding Bhd Cash Flow Conversion Efficiency
YSP Southeast Asia Holding Bhd cash flow conversion efficiency. Based on the latest financial reports, YSP Southeast Asia Holding Bhd (7178) has a cash flow conversion efficiency ratio of 0.066x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM28.53 Million ≈ $7.16 Million USD) by net assets (RM432.22 Million ≈ $108.52 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of YSP Southeast Asia Holding Bhd (2012–2025)
Cash flow conversion efficiency of YSP Southeast Asia Holding Bhd from 2012 to 2025. This chart illustrates how YSP Southeast Asia Holding Bhd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of YSP Southeast Asia Holding Bhd for real-time trading data and today's change.
YSP Southeast Asia Holding Bhd Cash Flow Conversion Ratio Explained
YSP Southeast Asia Holding Bhd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
YSP Southeast Asia Holding Bhd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of YSP Southeast Asia Holding Bhd ranked by their cash flow conversion efficiency. Also see 7178 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SLP Resources Bhd
KLSE:7248
|
0.081x |
|
Rani Therapeutics Holdings Inc
NASDAQ:RANI
|
-0.188x |
|
DENARIUS METALS CORP.
F:T7C0
|
-0.039x |
|
Creepy Jar SA
WAR:CRJ
|
0.241x |
|
Shanghai Lingang Holdings Co Ltd B
SHG:900928
|
-0.013x |
|
P.A. Resources Bhd
KLSE:7225
|
-0.020x |
|
Hainan Airlines Co Ltd B
SHG:900945
|
0.547x |
|
Conexeu Sciences Inc. Common Stock
NASDAQ:CNXU
|
-0.251x |
Annual Cash Flow Conversion Efficiency for YSP Southeast Asia Holding Bhd (2012–2025)
The table below shows the annual cash flow conversion efficiency of YSP Southeast Asia Holding Bhd from 2012 to 2025. Review YSP Southeast Asia Holding Bhd free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | RM425.70 Million ≈ $106.88 Million |
RM54.46 Million ≈ $13.67 Million |
0.128x | +5.26% |
| 2024-12-31 | RM409.02 Million ≈ $102.69 Million |
RM49.71 Million ≈ $12.48 Million |
0.122x | +32.17% |
| 2023-12-31 | RM395.06 Million ≈ $99.19 Million |
RM36.33 Million ≈ $9.12 Million |
0.092x | -29.17% |
| 2022-12-31 | RM372.16 Million ≈ $93.44 Million |
RM48.31 Million ≈ $12.13 Million |
0.130x | -29.31% |
| 2021-12-31 | RM346.50 Million ≈ $87.00 Million |
RM63.63 Million ≈ $15.98 Million |
0.184x | +593.57% |
| 2020-12-31 | RM342.60 Million ≈ $86.01 Million |
RM9.07 Million ≈ $2.28 Million |
0.026x | -73.32% |
| 2019-12-31 | RM328.19 Million ≈ $82.40 Million |
RM32.58 Million ≈ $8.18 Million |
0.099x | +54.77% |
| 2018-12-31 | RM315.05 Million ≈ $79.10 Million |
RM20.20 Million ≈ $5.07 Million |
0.064x | -32.73% |
| 2017-12-31 | RM289.51 Million ≈ $72.69 Million |
RM27.60 Million ≈ $6.93 Million |
0.095x | -37.56% |
| 2016-12-31 | RM274.41 Million ≈ $68.89 Million |
RM41.90 Million ≈ $10.52 Million |
0.153x | +49.30% |
| 2015-12-31 | RM264.00 Million ≈ $66.28 Million |
RM27.00 Million ≈ $6.78 Million |
0.102x | +74.59% |
| 2014-12-31 | RM239.00 Million ≈ $60.01 Million |
RM14.00 Million ≈ $3.51 Million |
0.059x | -55.09% |
| 2013-12-31 | RM230.00 Million ≈ $57.75 Million |
RM30.00 Million ≈ $7.53 Million |
0.130x | +71.10% |
| 2012-12-31 | RM223.00 Million ≈ $55.99 Million |
RM17.00 Million ≈ $4.27 Million |
0.076x | -- |
About YSP Southeast Asia Holding Bhd
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, an… Read more